Evidence map›Paper›PMID 30903514›Full record

ArticleClinical journal of gastroenterology2019

Immunomodulator-associated Epstein-Barr virus-positive mucocutaneous ulcer in a patient with refractory Crohn's disease.

Shinsaku Hamanaka, Tomoo Nakagawa, Satoshi Ota, Mana Iida, Yuki Ohta, Yusuke Isshiki, Shingo Kasamatsu, Hideaki Ishigami, Takashi Taida, Kenichiro Okimoto and 11 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Shinsaku HamanakaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, Chiba, 260-8670, Japan.
Tomoo NakagawaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, Chiba, 260-8670, Japan. tom20852@hospital.chiba-u.jp.
Satoshi OtaDepartment of Pathology, Chiba University Hospital, Chiba, Chiba, Japan.
Mana IidaDepartment of Pathology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan.
Yuki OhtaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, Chiba, 260-8670, Japan.
Yusuke IsshikiDepartment of Hematology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan.
Shingo KasamatsuDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, Chiba, 260-8670, Japan.
Hideaki IshigamiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, Chiba, 260-8670, Japan.
Takashi TaidaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, Chiba, 260-8670, Japan.
Kenichiro OkimotoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, Chiba, 260-8670, Japan.
Keiko SaitoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, Chiba, 260-8670, Japan.
Daisuke MaruokaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, Chiba, 260-8670, Japan.
Tomoaki MatsumuraDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, Chiba, 260-8670, Japan.
Chikako OhwadaDepartment of Hematology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan.
Masahiro TakeuchiDepartment of Hematology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan.
Emiko SakaidaDepartment of Hematology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan.
Makoto AraiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, Chiba, 260-8670, Japan.
Tatsuro KatsunoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, Chiba, 260-8670, Japan.
Chiaki NakasekoDepartment of Hematology, International University of Health and Welfare School of Medicine, Narita, Japan.
Yukio NakataniDepartment of Pathology, Chiba University Hospital, Chiba, Chiba, Japan.
Naoya KatoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, Chiba, 260-8670, Japan.
Chiba University · JPChiba University Hospital · JPInternational University of Health and Welfare · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epstein-Barr virus (EBV)-positive mucocutaneous ulcer is a B-cell lymphoproliferative disorder occurring in elderly or iatrogenic immunocompromised patients. We report a 27-year-old male patient with Crohn's disease (CD) who developed immunomodulator-associated lymphoproliferative disorder. The patient was diagnosed with CD at the age of 17 and was treated with maintenance therapy including high-dose infliximab and azathioprine. When he was admitted to our hospital with a diagnosis of intestinal obstruction, his abdominal computed tomography findings showed not only colonic wall thickening and narrowing of the descending colon but also multiple liver tumor lesions. His ileus symptom improved with conservative therapy, and a pathological evaluation of the tissue biopsy specimens from the descending colon and liver lesions indicated a morphological diagnosis of EBV-positive diffuse large B-cell lymphoma. This was a case of iatrogenic immunodeficiency-associated lymphoproliferative disorder due to an immunomodulator. The treatment was initiated with chemotherapy, but he died of disease progression 10 months after the diagnosis of lymphoma. Although cases of lymphoproliferative disorder due to treatment modalities used for CD are rare in Japan, an increase in the risk of lymphoproliferative diseases should be considered in patients with CD treated with immunomodulatory agents.

Indexed as

AdultColonic NeoplasmsColonoscopyCrohn DiseaseEpstein-Barr Virus InfectionsFatal OutcomeHumansImmunocompromised HostImmunosuppressive AgentsLiver NeoplasmsLymphoma, Large B-Cell, DiffuseMaleTomography, X-Ray ComputedUlcerImmunosuppressive AgentsCrohn’s diseaseEpstein–Barr virusEpstein–Barr virus-positive mucocutaneous ulcerImmunomodulatory agentMalignant lymphoma

Identifiers

PMID30903514
OpenAlexW2923756722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.